Selective metabolic regulations by p53 mutant variants in pancreatic cancer
Abstract Background Approximately half of all human cancers harbour mutations in the p53 gene, leading to the generation of neomorphic p53 mutant proteins. These mutants can exert gain-of-function (GOF) effects, potentially promoting tumour progression. However, the clinical significance of p53 GOF...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-024-03232-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850107434633265152 |
|---|---|
| author | Sabrina Caporali Alessio Butera Alessia Ruzza Carlotta Zampieri Marina Bantula’ Sandra Scharsich Anna-Katerina Ückert Ivana Celardo Ian U. Kouzel Luigi Leanza Andreas Gruber Joan Montero Angelo D’Alessandro Thomas Brunner Marcel Leist Ivano Amelio |
| author_facet | Sabrina Caporali Alessio Butera Alessia Ruzza Carlotta Zampieri Marina Bantula’ Sandra Scharsich Anna-Katerina Ückert Ivana Celardo Ian U. Kouzel Luigi Leanza Andreas Gruber Joan Montero Angelo D’Alessandro Thomas Brunner Marcel Leist Ivano Amelio |
| author_sort | Sabrina Caporali |
| collection | DOAJ |
| description | Abstract Background Approximately half of all human cancers harbour mutations in the p53 gene, leading to the generation of neomorphic p53 mutant proteins. These mutants can exert gain-of-function (GOF) effects, potentially promoting tumour progression. However, the clinical significance of p53 GOF mutations, as well as the selectivity of individual variants, remains controversial and unclear. Methods To elucidate the metabolic regulations and molecular underpinnings associated with the specific p53R270H and p53R172H mutant variants (the mouse equivalents of human p53R273H and p53R175H, respectively), we employed a comprehensive approach. This included integrating global metabolomic analysis with epigenomic and transcriptomic profiling in mouse pancreatic cancer cells. Additionally, we assessed metabolic parameters such as oxygen consumption rate and conducted analyses of proliferation and cell–cell competition to validate the biological impact of metabolic changes on pancreatic ductal adenocarcinoma (PDAC) phenotype. Our findings were further corroborated through analysis of clinical datasets from human cancer cohorts. Results Our investigation revealed that the p53R270H variant, but not p53R172H, sustains mitochondrial function and energy production while also influencing cellular antioxidant capacity. Conversely, p53R172H, while not affecting mitochondrial metabolism, attenuates the activation of pro-tumorigenic metabolic pathways such as the urea cycle. Thus, the two variants selectively control different metabolic pathways in pancreatic cancer cells. Mechanistically, p53R270H induces alterations in the expression of genes associated with oxidative stress and reduction in mitochondrial respiration. In contrast, p53R172H specifically impacts the expression levels of enzymes involved in the urea metabolism. However, our analysis of cell proliferation and cell competition suggested that the expression of either p53R270H or p53R172H does not influence confer any selective advantage to this cellular model in vitro. Furthermore, assessment of mitochondrial priming indicated that the p53R270H-driven mitochondrial effect does not alter cytochrome c release or the apoptotic propensity of pancreatic cancer cells. Conclusions Our study elucidates the mutant-specific impact of p53R270H and p53R172H on metabolism of PDAC cancer cells, highlighting the need to shift from viewing p53 mutant variants as a homogeneous group of entities to a systematic assessment of each specific p53 mutant protein. Moreover, our finding underscores the importance of further exploring the significance of p53 mutant proteins using models that more accurately reflect tumor ecology. |
| format | Article |
| id | doaj-art-2c9b386036f84eaf9c888f23c8e8570a |
| institution | OA Journals |
| issn | 1756-9966 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj-art-2c9b386036f84eaf9c888f23c8e8570a2025-08-20T02:38:35ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662024-11-0143111710.1186/s13046-024-03232-3Selective metabolic regulations by p53 mutant variants in pancreatic cancerSabrina Caporali0Alessio Butera1Alessia Ruzza2Carlotta Zampieri3Marina Bantula’4Sandra Scharsich5Anna-Katerina Ückert6Ivana Celardo7Ian U. Kouzel8Luigi Leanza9Andreas Gruber10Joan Montero11Angelo D’Alessandro12Thomas Brunner13Marcel Leist14Ivano Amelio15Chair for Systems Toxicology, Department of Biology, University of KonstanzChair for Systems Toxicology, Department of Biology, University of KonstanzChair for Systems Toxicology, Department of Biology, University of KonstanzDepartment of Pathology, University of California San Diego School of MedicineDepartment of Biomedical Sciences, Universitat de BarcelonaChair for Systems Toxicology, Department of Biology, University of KonstanzChair for in Vitro Toxicology and Biomedicine, University of KonstanzChair for in Vitro Toxicology and Biomedicine, University of KonstanzApplied Bioinformatic Group, University of KonstanzDepartment of Biology, University of PaduaApplied Bioinformatic Group, University of KonstanzDepartment of Biomedical Sciences, Universitat de BarcelonaUniversity of Colorado Anschutz Medical CampusChair for in Biochemical Pharmacology, University of KonstanzChair for in Vitro Toxicology and Biomedicine, University of KonstanzChair for Systems Toxicology, Department of Biology, University of KonstanzAbstract Background Approximately half of all human cancers harbour mutations in the p53 gene, leading to the generation of neomorphic p53 mutant proteins. These mutants can exert gain-of-function (GOF) effects, potentially promoting tumour progression. However, the clinical significance of p53 GOF mutations, as well as the selectivity of individual variants, remains controversial and unclear. Methods To elucidate the metabolic regulations and molecular underpinnings associated with the specific p53R270H and p53R172H mutant variants (the mouse equivalents of human p53R273H and p53R175H, respectively), we employed a comprehensive approach. This included integrating global metabolomic analysis with epigenomic and transcriptomic profiling in mouse pancreatic cancer cells. Additionally, we assessed metabolic parameters such as oxygen consumption rate and conducted analyses of proliferation and cell–cell competition to validate the biological impact of metabolic changes on pancreatic ductal adenocarcinoma (PDAC) phenotype. Our findings were further corroborated through analysis of clinical datasets from human cancer cohorts. Results Our investigation revealed that the p53R270H variant, but not p53R172H, sustains mitochondrial function and energy production while also influencing cellular antioxidant capacity. Conversely, p53R172H, while not affecting mitochondrial metabolism, attenuates the activation of pro-tumorigenic metabolic pathways such as the urea cycle. Thus, the two variants selectively control different metabolic pathways in pancreatic cancer cells. Mechanistically, p53R270H induces alterations in the expression of genes associated with oxidative stress and reduction in mitochondrial respiration. In contrast, p53R172H specifically impacts the expression levels of enzymes involved in the urea metabolism. However, our analysis of cell proliferation and cell competition suggested that the expression of either p53R270H or p53R172H does not influence confer any selective advantage to this cellular model in vitro. Furthermore, assessment of mitochondrial priming indicated that the p53R270H-driven mitochondrial effect does not alter cytochrome c release or the apoptotic propensity of pancreatic cancer cells. Conclusions Our study elucidates the mutant-specific impact of p53R270H and p53R172H on metabolism of PDAC cancer cells, highlighting the need to shift from viewing p53 mutant variants as a homogeneous group of entities to a systematic assessment of each specific p53 mutant protein. Moreover, our finding underscores the importance of further exploring the significance of p53 mutant proteins using models that more accurately reflect tumor ecology.https://doi.org/10.1186/s13046-024-03232-3Tumour suppressorGain-of-functionCancer MetabolismAnti-oxidant capacity |
| spellingShingle | Sabrina Caporali Alessio Butera Alessia Ruzza Carlotta Zampieri Marina Bantula’ Sandra Scharsich Anna-Katerina Ückert Ivana Celardo Ian U. Kouzel Luigi Leanza Andreas Gruber Joan Montero Angelo D’Alessandro Thomas Brunner Marcel Leist Ivano Amelio Selective metabolic regulations by p53 mutant variants in pancreatic cancer Journal of Experimental & Clinical Cancer Research Tumour suppressor Gain-of-function Cancer Metabolism Anti-oxidant capacity |
| title | Selective metabolic regulations by p53 mutant variants in pancreatic cancer |
| title_full | Selective metabolic regulations by p53 mutant variants in pancreatic cancer |
| title_fullStr | Selective metabolic regulations by p53 mutant variants in pancreatic cancer |
| title_full_unstemmed | Selective metabolic regulations by p53 mutant variants in pancreatic cancer |
| title_short | Selective metabolic regulations by p53 mutant variants in pancreatic cancer |
| title_sort | selective metabolic regulations by p53 mutant variants in pancreatic cancer |
| topic | Tumour suppressor Gain-of-function Cancer Metabolism Anti-oxidant capacity |
| url | https://doi.org/10.1186/s13046-024-03232-3 |
| work_keys_str_mv | AT sabrinacaporali selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT alessiobutera selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT alessiaruzza selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT carlottazampieri selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT marinabantula selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT sandrascharsich selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT annakaterinauckert selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT ivanacelardo selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT ianukouzel selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT luigileanza selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT andreasgruber selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT joanmontero selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT angelodalessandro selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT thomasbrunner selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT marcelleist selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer AT ivanoamelio selectivemetabolicregulationsbyp53mutantvariantsinpancreaticcancer |